Michael Lukason

1.3k citations

20 papers · 917 indexed · h-index 14

Ophthalmology top 2%
- Retinal Diseases and Treatments 4
- Retinal and Optic Conditions 3
Genetics top 5%
- Virus-based gene therapy research 9
Business and International Management top 10%
Molecular Biology top 10%
- Retinal Development and Disorders 8
- RNA Interference and Gene Delivery 8
- CRISPR and Genetic Engineering 2
Aging
Infectious Diseases
- Viral gastroenteritis research and epidemiology 2
Oncology
- CAR-T cell therapy research 2

Co-authors: Seng H. Cheng Abraham Scaria Elizabeth Barry Guo-Xiang Ruan Dan Yu Ronald K. Scheule Samuel C. Wadsworth Jennifer D. Tousignant
Cited by: Ophthalmology Genetics Business and International Management
Journals: Molecular Therapy (9 papers)Human Gene Therapy (7 papers)Gene Therapy (2 papers)
Partner nations: United States Switzerland

In The Last Decade

Michael Lukason

20 papers receiving 883 citations

Peers

Countries citing papers authored by Michael Lukason

Since Specialization

Citations

This map shows the geographic impact of Michael Lukason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lukason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lukason more than expected).

Fields of papers citing papers by Michael Lukason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lukason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lukason. The network helps show where Michael Lukason may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Lukason, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Lukason Line = papers co-authored together Michael Lukason links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis Molecular Therapy — Methods & Clinical Development ·Sanford L. Boye,Catherine R. O’Riordan,James Morris,Michael Lukason,David M. Compton,Rena Baek,Aurora Reid,Jim Peterson,Diego Fajardo,頼子大脇,Abraham Scaria,Alison McVie‐Wylie	2022	4
2	Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea Human Gene Therapy ·Iskender Alp Humbaraci,Jennifer A. Sullivan,Lin Liu,李同文,Michael Lukason,ਜਗਤਾਰ ਸਿੰਘ -,Zhengyu Luo,Xiaoying Jin,Kollu N. Rao,Catherine R. O’Riordan	2020	25
3	Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain Gene Therapy ·Jennifer A. Sullivan,Lisa M. Stanek,Michael Lukason,Jie Bu,Pamela Soraya,Elizabeth Barry,Catherine R. O’Riordan,Lamya S. Shihabuddin,Seng H. Cheng,Abraham Scaria	2018	27
4	CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10 Molecular Therapy ·Guo-Xiang Ruan,Elizabeth Barry,Dan Yu,Michael Lukason,Seng H. Cheng,Abraham Scaria	2017	212
5	301. AAV Capsid Engineering to Improve Transduction in Retina and Brain Molecular Therapy ·Jennifer A. Sullivan,Lisa M. Stanek,Michael Lukason,Elizabeth Barry,Afriza Leonita,J. Bradley Morris,Loon Karan Raika,Jang Young Charles,Jie Bu,Lamya S. Shihabuddin,Seng H. Cheng,Abraham Scaria	2016	3
6	329. Using CRISPR/Cas9 as a Therapeutic Approach for Leber Congenital Amaurosis 10 (LCA10) Molecular Therapy ·Guo-Xiang Ruan,Elizabeth Barry,Michael Lukason,Seng H. Cheng,Abraham Scaria	2016	14
7	Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule Molecular Therapy ·Michael Lukason,Sheppard Adrian,Hillard Rubin,Peter Pecháň,Qiuhong Li,Ivana K. Kim,Szilárd Kiss,Yevgeni A. Chashchin,Margaret E. Collins,Joan W. Miller,William W. Hauswirth,Timothy K. MacLachlan,Samuel C. Wadsworth,Abraham Scaria	2010	67
8	Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration Molecular Therapy ·Timothy K. MacLachlan,Michael Lukason,Margaret E. Collins,Robert J. Munger,Christine A. Waters,Runda Liu,McKeown Mj,Sheppard Adrian,J. Bradley Morris,Roberto Calcedo,Gábor Veres,Abraham Scaria,Ali Murtaza,Samuel C. Wadsworth	2010	136
9	Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy Molecular Therapy ·Gregory D Hurlbut,Robin J. Ziegler,Jennifer B. Nietupski,Joseph W. Foley,Lisa Woodworth,YongBok Lee,Scott D. Bercury,Nilesh Pande,David W. Souza,Mark P. Bree,Michael Lukason,John Marshall,Seng H. Cheng,Ronald K. Scheule	2010	117
10	Cytotoxic T Lymphocyte Responses to Transgene Product, Not Adeno-Associated Viral Capsid Protein, Limit Transgene Expression in Mice Human Gene Therapy ·William Siders,Jacqueline D. Shields,Johanne Kaplan,Michael Lukason,Lisa Woodworth,Sam Wadsworth,Abraham Scaria	2009	17
11	Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization Gene Therapy ·Peter Pecháň,Hillard Rubin,Michael Lukason,Chun Chen,Sheppard Adrian,William W. Hauswirth,Sam Wadsworth,Abraham Scaria	2008	83
12	Cytotoxic T-Lymphocyte (CTL) responses to the transgene product and not AAV capsid protein limit transgene expression in mice Human Gene Therapy ·William Siders,Jacqueline D. Shields,Johanne Kaplan,Michael Lukason,Lisa Woodworth,Samuel C. Wadsworth,Abraham Scaria	2008	3
13	883. AAV-2 Based Gene Therapy Using Novel Anti-VEGF Molecules for Inhibition of Angiogenesis in the Eye Molecular Therapy ·Abraham Scaria,Peter Pecháň,Hillard Rubin,Michael Lukason,Elizabeth Barry,V. Leclerc,Huawei Qiu,Qiuhong Li,Jim Peterson,William W. Hauswirth,Samuel C. Wadsworth	2006	1
14	Adenovirus-Transduced Lung as a Portal for Delivering α-Galactosidase A into Systemic Circulation for Fabry Disease Molecular Therapy ·Chester Li,Robin J. Ziegler,Maribeth Cherry,Michael Lukason,Robert J. Desnick,Nelson S. Yew,Seng H. Cheng	2002	29
15	Adenoviral Vector Expressing ICP47 Inhibits Adenovirus-Specific Cytotoxic T Lymphocytes in Nonhuman Primates Molecular Therapy ·Abraham Scaria,Jennifer A. Sullivan,Judith A. St. George,Johanne Kaplan,Michael Lukason,James E. Morris,حسام الدين خليل محمد,جبار كاظم شنبارة العويدي,Richard J. Gregory,Samuel C. Wadsworth	2000	10
16	Aerosolization of Cationic Lipid:pDNA Complexes— In Vitro Optimization of Nebulizer Parameters for Human Clinical Studies Human Gene Therapy ·Simon J. Eastman,Jennifer D. Tousignant,Michael Lukason,S. N. Dubey,Seng H. Cheng,Ronald K. Scheule	1998	22
17	Safety of Airway Gene Transfer with Ad2/CFTR2: Aerosol Administration in the Nonhuman Primate Human Gene Therapy ·Ruth J. McDonald,Michael Lukason,Otto G. Raabe,Don R. Canfield,Rupinder Kular,Johanne Kaplan,Samuel C. Wadsworth,Judith A. St. George	1997	21
18	A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung Human Gene Therapy ·Simon J. Eastman,Michael Lukason,Jennifer D. Tousignant,Heather Murray,Timothy P. Walker,Judith A. St. George,Geoffrey Y. Akita,Maribeth Cherry,Seng H. Cheng,Ronald K. Scheule	1997	64
19	Optimization of Formulations and Conditions for the Aerosol Delivery of Functional Cationic Lipid:DNA Complexes Human Gene Therapy ·Simon J. Eastman,Jennifer D. Tousignant,Michael Lukason,Heather Murray,Craig Siegel,Paul J. Constantino,David J. Harris,Seng H. Cheng,Ronald K. Scheule	1997	60
20	Modulation of human plasma fibronectin levels following exercise. PubMed ·David A. DuBose,Lawrence E. Armstrong,W J Kraemer,Michael Lukason	1989	2

About Michael Lukason

Michael Lukason is a scholar working on Ophthalmology, Genetics and Molecular Biology, having authored 20 papers that have together received 917 indexed citations. Recurring topics across this work include Virus-based gene therapy research (9 papers), Retinal Development and Disorders (8 papers), RNA Interference and Gene Delivery (8 papers), Retinal Diseases and Treatments (4 papers), Retinal and Optic Conditions (3 papers), Viral gastroenteritis research and epidemiology (2 papers), CRISPR and Genetic Engineering (2 papers) and CAR-T cell therapy research (2 papers). The work is most often cited by research in Ophthalmology (204 citations), Genetics (387 citations) and Business and International Management (24 citations). Michael Lukason has collaborated with scholars based in United States and Switzerland. Frequent co-authors include Seng H. Cheng, Abraham Scaria, Elizabeth Barry, Guo-Xiang Ruan, Dan Yu, Ronald K. Scheule, Samuel C. Wadsworth, Jennifer D. Tousignant, Simon J. Eastman and William W. Hauswirth. Their work appears in journals such as Molecular Therapy, Human Gene Therapy, Gene Therapy, Molecular Therapy — Methods & Clinical Development and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact